R1 Therapeutics Deal History & Licensing Activity
R1 Therapeutics is a life sciences. Over the past three years, R1 Therapeutics has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Other
R1 Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving R1 Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AP306 | Alebund Pharmaceuticals | Small Molecules | Phase 2 | license | Mar 2026 |
R1 Therapeutics Pipeline Focus
Therapeutic areas and modalities where R1 Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
R1 Therapeutics Strategic Signals
Key indicators of R1 Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches R1 Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About R1 Therapeutics Licensing & Deal Activity
R1 Therapeutics is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, R1 Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for R1 Therapeutics include Other (2 deals and trials). In terms of modality, R1 Therapeutics has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for R1 Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against R1 Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.